Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Richland, WA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Richland, WA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntington, WV
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntington, WV
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Crosse, WI
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Crosse, WI
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marshfield, WI
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marshfield, WI
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Bahía Blanca,
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Bahía Blanca,
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Jose, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Jose, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marlton, NJ
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Athens, TN
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Athens, TN
Click here to add this to my saved trials
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
A Randomized Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
A Randomized Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Rehabilitating Corticospinal Control of Walking
Rehabilitation of Corticospinal Control of Walking Following Stroke
Status: Enrolling
Updated:  12/31/1969
North Florida/South Georgia Veterans Health System, Gainesville, FL
mi
from
Gainesville, FL
Rehabilitating Corticospinal Control of Walking
Rehabilitation of Corticospinal Control of Walking Following Stroke
Status: Enrolling
Updated: 12/31/1969
North Florida/South Georgia Veterans Health System, Gainesville, FL
mi
from
Gainesville, FL
Click here to add this to my saved trials
Rehabilitating Corticospinal Control of Walking
Rehabilitation of Corticospinal Control of Walking Following Stroke
Status: Enrolling
Updated:  12/31/1969
Brooks Rehabilitation Hospital
mi
from
Jacksonville, FL
Rehabilitating Corticospinal Control of Walking
Rehabilitation of Corticospinal Control of Walking Following Stroke
Status: Enrolling
Updated: 12/31/1969
Brooks Rehabilitation Hospital
mi
from
Jacksonville, FL
Click here to add this to my saved trials
FAAH Inhibitor Trial for Adults With Tourette Syndrome
FAAH Inhibitor Trial for Adults With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Connecticut Mental Health Center
mi
from
New Haven, CT
FAAH Inhibitor Trial for Adults With Tourette Syndrome
FAAH Inhibitor Trial for Adults With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam
Status: Enrolling
Updated:  12/31/1969
Cooper Universtiy Hospital
mi
from
Camden, NJ
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam
Status: Enrolling
Updated: 12/31/1969
Cooper Universtiy Hospital
mi
from
Camden, NJ
Click here to add this to my saved trials
Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI
Effect of Administration of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Patients With Persistent Symptoms During the Subacute Period After TBI
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI
Effect of Administration of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Patients With Persistent Symptoms During the Subacute Period After TBI
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
rTMS to Improve Cognitive Function in TBI
Repetitive Transcranial Magnetic Stimulation to Improve Cognitive Function in TBI
Status: Enrolling
Updated:  12/31/1969
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
rTMS to Improve Cognitive Function in TBI
Repetitive Transcranial Magnetic Stimulation to Improve Cognitive Function in TBI
Status: Enrolling
Updated: 12/31/1969
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
El Cajon, CA
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
El Cajon, CA
Click here to add this to my saved trials
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Gainesville, GA
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Gainesville, GA
Click here to add this to my saved trials
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rochester, MN
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
New York, NY
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
Denver, CO
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Ciudad Autonoma de Bs As,
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Ciudad Autonoma de Bs As,
Click here to add this to my saved trials
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy
The Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy
The Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis
Autologous Adipose Stromal Vascular Fraction Outcomes Research Study
Status: Enrolling
Updated:  12/31/1969
StemGenex
mi
from
San Diego, CA
Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis
Autologous Adipose Stromal Vascular Fraction Outcomes Research Study
Status: Enrolling
Updated: 12/31/1969
StemGenex
mi
from
San Diego, CA
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ventura, CA
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ventura, CA
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boise, ID
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Reno, NV
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Paul, MN
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Paul, MN
Click here to add this to my saved trials
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Redwood City, CA
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Redwood City, CA
Click here to add this to my saved trials
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated:  12/31/1969
Harvard Mass General
mi
from
Boston, MA
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated: 12/31/1969
Harvard Mass General
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated:  12/31/1969
Boston University
mi
from
Boston, MA
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated: 12/31/1969
Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials